论文部分内容阅读
目的分析研讨米力农治疗慢性肺心病合并心力衰竭的临床疗效。方法本文纳入研究对象来自2015-2016年期间收治确认合并心力衰竭的慢性肺心病患者资料,抽取62例,将62例患者按入院单双顺序将其分两组,31例对照组(接受常规综合治疗)和31例研究组(接受米力农注射液治疗),将两组患者治疗效果纳入对比研讨中。结果经治疗之后,研究组的治疗总有效率(93.55%)比对照组(77.42%)高,两组对比有统计学意义(P<0.05);研究组患者不良反应发生率9.68%比对照组25.81%低,组间数据有统计学意义(P<0.05)。结论采用米力农治疗慢性肺心病合并心力衰竭,其疗效显著,安全可靠,可作为理想药物之一,值得临床应用及推广。
Objective To analyze and discuss the clinical effect of Milrinone in treating chronic pulmonary heart disease complicated with heart failure. Methods The data collected from 62 patients with chronic pulmonary heart disease admitted to confirmed heart failure during 2015-2016 were included in this study. Sixty-two patients were divided into two groups according to the order of hospital admission, and 31 patients in the control group Treatment) and 31 cases (receiving Milrinone injection treatment), the treatment effect of two groups of patients included in the comparative study. Results After treatment, the total effective rate of the study group (93.55%) was higher than that of the control group (77.42%), the difference was statistically significant (P <0.05). The adverse reaction rate of the study group was 9.68% 25.81% lower, the data between groups was statistically significant (P <0.05). Conclusion Milrinone treatment of chronic pulmonary heart disease with heart failure, its efficacy is significant, safe and reliable, can be used as one of the ideal drugs, it is worth clinical application and promotion.